tiprankstipranks
Trending News
More News >
Biotest AG (GB:0N6Z)
LSE:0N6Z
Advertisement

Biotest (0N6Z) Price & Analysis

Compare
0 Followers

0N6Z Stock Chart & Stats


0N6Z FAQ

What was Biotest AG’s price range in the past 12 months?
Biotest AG lowest share price was €41.00 and its highest was €42.00 in the past 12 months.
    What is Biotest AG’s market cap?
    Biotest AG’s market cap is €1.40B.
      When is Biotest AG’s upcoming earnings report date?
      Biotest AG’s upcoming earnings report date is Nov 10, 2025 which is in 73 days.
        How were Biotest AG’s earnings last quarter?
        Currently, no data Available
        Is Biotest AG overvalued?
        According to Wall Street analysts Biotest AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Biotest AG pay dividends?
          Biotest AG does not currently pay dividends.
          What is Biotest AG’s EPS estimate?
          Biotest AG’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Biotest AG have?
          Biotest AG has 19,785,727 shares outstanding.
            What happened to Biotest AG’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Biotest AG?
            Currently, no hedge funds are holding shares in GB:0N6Z

            Biotest Stock Smart Score

            4
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Company Description

            Biotest AG

            Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

            Biotest (0N6Z) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Eckert & Ziegler Strahlen und Medizintechnik
            Epigenomics
            Evotec
            Medios AG
            Formycon AG
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis